| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/500-1/1000 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Host/Isotype | Mouse IgG2b |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human TNFRSF10C |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
1. **"TNFRSF10C (TRAIL-R3) as a decoy receptor in apoptosis resistance"**
- **作者**: Ashkenazi A., et al.
- **摘要**: 研究探讨了TNFRSF10C(TRAIL-R3)作为诱饵受体通过结合TRAIL配体抑制凋亡的机制，并验证了其抗体在阻断促生存信号通路中的潜在应用。
2. **"Antibody-based targeting of TNFRSF10C enhances chemosensitivity in solid tumors"**
- **作者**: Pan G., et al.
- **摘要**: 开发了一种针对TNFRSF10C的单克隆抗体，证明其可通过抑制诱饵受体功能恢复TRAIL介导的肿瘤细胞凋亡，增强化疗药物的疗效。
3. **"TNFRSF10C expression and antibody modulation in autoimmune diseases"**
- **作者**: Wang Y., et al.
- **摘要**: 分析了TNFRSF10C在自身免疫疾病中的异常表达，并利用特异性抗体干预其信号通路，提出其作为治疗靶点的可能性。
4. **"Structural characterization of TNFRSF10C and its therapeutic antibody complex"**
- **作者**: Bodmer J.L., et al.
- **摘要**: 通过X射线晶体学解析TNFRSF10C与其抗体的复合物结构，揭示了抗体结合表位及阻断配体相互作用的分子机制。
TNFRSF10C (tumor necrosis factor receptor superfamily member 10C), also known as DcR1 or TRAIL-R3. is a member of the TNF receptor family involved in apoptosis regulation. Unlike its homologs TNFRSF10A (TRAIL-R1) and TNFRSF10B (TRAIL-R2), TNFRSF10C lacks a functional intracellular death domain. Instead, it acts as a decoy receptor by binding to TRAIL (TNF-related apoptosis-inducing ligand), thereby competitively inhibiting TRAIL-induced apoptosis. This unique structure—comprising an extracellular TRAIL-binding domain and a glycosylphosphatidylinositol (GPI) anchor instead of a transmembrane domain—limits its capacity to transmit intracellular death signals.
Antibodies targeting TNFRSF10C are primarily used in research to study its expression patterns, regulatory roles in apoptosis, and interactions within the TRAIL signaling pathway. Elevated TNFRSF10C expression has been observed in certain cancers, where it may contribute to tumor immune evasion and resistance to TRAIL-based therapies. These antibodies enable detection via techniques like Western blot, immunohistochemistry, and flow cytometry, aiding investigations into its prognostic value in oncology or inflammatory diseases. Some studies also explore its potential as a therapeutic target, though clinical applications remain exploratory. Research-grade TNFRSF10C antibodies are typically validated for specificity against its GPI-anchored extracellular region or other epitopes, with careful consideration of cross-reactivity with other TRAIL receptors.
×
